𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Obstacles and opportunities for the use of health-related quality-of-life assessment in pediatric cancer clinical trials (discussion)

✍ Scribed by Brad H. Pollock

Publisher
John Wiley and Sons
Year
1999
Tongue
French
Weight
63 KB
Volume
83
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Completion rates in health-related quali
Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group
✍ David Osoba; Benny Zee πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 143 KB πŸ‘ 1 views

The approach of the National Cancer Institute of Canada Clinical Trials Group to measuring compliance, that is, completion rates, for health-related quality of life questionnaires is presented. Completion rates can be measured at the institutional, patient, questionnaire and item levels for baseline

The Pediatric Cancer Quality of Life Inv
The Pediatric Cancer Quality of Life Inventory: A modular approach to measuring health-related quality of life in children with cancer
✍ Michael Seid; James W. Varni; Cheryl A. Rode; Ernest R. Katz πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 89 KB πŸ‘ 2 views

Measurement of pediatric cancer patients' health-related quality of life (HRQL) in phase III randomized, controlled clinical trials is being recognized increasingly as an essential component in evaluating the comprehensive health outcomes of modern anti-neoplastic treatment protocols. Use of a brief

Practical issues in quality of life asse
Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Research
✍ JΓΌrg Bernhard; Heidi Gusset; Christoph HΓΌrny πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 130 KB πŸ‘ 2 views

Quality of life (QOL) assessment has become an integrated part in some advanced disease trials and to a lesser extent in early disease trials conducted by the Swiss Group for Clinical Cancer Research (SAKK). In general, the concept of QOL endpoints and the additional work of collecting these data is